Stefan Grass
Geen lopende functies
Vermogen: 66 121 $ op 31-05-2024
Loopbaan van Stefan Grass
Eerdere bekende functies van Stefan Grass
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
CSL Behring AB
 CSL Behring AB Pharmaceuticals: MajorHealth Technology CSL Behring AB develops, manufactures, and markets protein-based therapies in the bleeding disorders, critical care, immunoglobulins, and pulmonary areas. It offers therapies such as plasma-derived and recombinant coagulation factors, immunoglobulins for the treatment of primary immune deficiency, alpha1-proteinase inhibitor for chronic A1-PI augmentation therapy, and C1-INH concentrate. The company was founded in 1904 and is headquartered in Danderyd, Sweden. | Corporate Officer/Principal | - | - |
| BACTIGUARD HOLDING AB | Hoofd Techniek/Wetenschap/O&O | 31-10-2019 | - |
Opleiding van Stefan Grass
| Karolinska Institutet | Doctorate Degree |
Statistieken
Internationaal
| Zweden | 4 |
Operationeel
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
| Graduate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| BACTIGUARD HOLDING AB | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
CSL Behring AB
CSL Behring AB Pharmaceuticals: MajorHealth Technology CSL Behring AB develops, manufactures, and markets protein-based therapies in the bleeding disorders, critical care, immunoglobulins, and pulmonary areas. It offers therapies such as plasma-derived and recombinant coagulation factors, immunoglobulins for the treatment of primary immune deficiency, alpha1-proteinase inhibitor for chronic A1-PI augmentation therapy, and C1-INH concentrate. The company was founded in 1904 and is headquartered in Danderyd, Sweden. | Health Technology |
- Beurs
- Insiders
- Stefan Grass
- Ervaring
